Bookmark and Share

Last Minute:          For more news, click here.

Remember me? 

PS: The quotes after 2017-05-12 are still temporary and may have for that reason the Open values wrong until furter updates...
Change to Biogen Idec Inc. Static Chart

Rise of
+3.85 (+1.24%) Biogen Idec Inc. - [Ticker: BIIB]Chart Biogen Idec Inc.  News Biogen Idec Inc.  Download Historical Prices for Metastock Biogen Idec Inc. and Others  Technical Analysis Biogen Idec Inc.  
Last Trade315.51Last Trade Time2017-11-01 - 19:35:00
Variation+3.85 (+1.24%)Open312.75
Volume1,047,609Average Volume (3m)0
YieldBid / Ask315.47 x 300 - 315.59 x 200
Former Close311.6652 Week Range[0.00 - 0.00]
Ex-Dividend DateDividend Payment
Market Capitalization0 1 Year Price-Target0.00
Note: The data may have some minutes of delay.

 News about Biogen Idec Inc. [BIIB]:   (ordered by relevance)
Where Biogen Stands With Analysts - Benzinga  Benzinga Biogen Alzheimer's Drug Shows Brain Swelling In 35% Of Patients  Benzinga Biogen Loses Bid To Revive Tecfidera Drug Patent: Bloomberg - Benzinga  Benzinga Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients - Benzinga  Benzinga Is Biogen Inc (BIIB) a Stock to Watch After Losing -3.00% This Week?  InvestorsObserver Plasma Expanders Market: Rising number of surgeries is expected to drive the market  BioSpace Biogen (BIIB) Stock Rises After Reporting Positive Data in Phase 3 Alzheimer's Trial  InvestorsObserver Workable Strategic Report on Solid Tumors Treatment Market by Forecast to 2027 with Covered Top Companies like Abbott Laboratories Inc., Biogen Idec Incorporated, AstraZeneca Plc  Medgadget Will Biogen Stock Rise After The Recent 6% Fall?  Forbes Aduhelm's 'Blockbuster Potential' Is Underappreciated, Says Biogen Analyst - Benzinga  Benzinga UPDATE: Biogen Shares Halted Ahead Of FDA Decision On Co.'s Alzheimer's Candidate, Aducanumab Monday  Benzinga Biogen Stock To See Much Higher Levels After A 38% Rise Yesterday  Forbes Here?s Why Biogen Stock Can Offer Over 35% Gains  Forbes Expert Ratings For Biogen - Benzinga  Benzinga Biogen Drops Idec From Name  Wall Street Journal Biogen Idec Becomes Biogen  Business Wire Alzheimer's drug from Biogen wins US approval  Financial Times Biogen Stock: With Alzheimer's Treatment In FDA Court, Is BIIB Stock A Buy In January 2021?  Investor's Business Daily Biogen bats aside Aduhelm jitters with confident third quarter  The Pharma Letter Biogen Idec: A Great Company, But Not An Alpha Opportunity  Seeking Alpha Biogen/Samsung Approval of BYOOVIZ? | Goodwin - JDSupra  JD Supra How Biogen Idec Inc. Uses Materiality Assessments to...  3BL Media Biogen Idec Stock Hits New 52-Week High (BIIB) Biogen launches new trial of Alzheimer's drug aducanumab  McKnight's Long Term Care News Biogen Idec (NASDAQ: BIIB) will add 100 workers in North Carolina's Research Triangle Park - Triangle Business Journal  Triangle Business Journal Why Biogen's Fortunes Hinge On Aducanumab Approval - Benzinga  Benzinga Biogen shares leap after ?substantial evidence? Alzheimer?s drug is effective  Financial Times Cipla receives final approval for generic version of Biogen IDEC Inc.'s Tecfidera® (Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pack)  PRNewswire Baidu And Nvidia Lead The QQQ Lower Thursday - Benzinga  Benzinga Biogen Idec's Plegridy approved in Europe for relapsing-remitting multiple sclerosis  The Pharma Letter Biogen Idec's Strategy For Neurology RD Success  Life Science Leader Magazine Biogen Inc. (BIIB) Stock Price Today, Quote & News  Seeking Alpha Biogen Idec (BIIB) shifts Machelle Sanders from head of RTP manufacturing to lead multiple sclerosis development - Triangle Business Journal  Triangle Business Journal Biogen's Case For Aduhelm For Alzheimer's  Seeking Alpha Is Biogen Getting Desperate?  Motley Fool Subcutaneous Biologics Market Market to See Huge Growth by 2030 | Abbott Laboratories, Pfizer Inc., Genentech Inc., Novartis AG, Biogen Idec  Medgadget Biogen Idec to Acquire Stromedix  Business Wire Biogen Agrees to Pay $22 Million to Resolve Allegations that it Paid Kickbacks Through Two Co-Pay Foundations  Department of Justice Here?s what?s weighing down this biotech stock  CNBC Biogen Idec scores lung disease drug in $562.5M buyout of Stromedix  FierceBiotech Biogen Idec provides coach commuting for suburban workers  Boston Globe Biogen Idec Moves Aggressively, Advances Alzheimer Drug InTo Phase 3  Clinical Leader Biogen Idec grabs Convergence, neuropathic pain portfolio in $675M buyout  FierceBiotech Quintiles and Biogen Idec Announce Comprehensive Clinical Development Partnership  Business Wire How Biogen Makes Money: Treatments for Neurological Disorders  Investopedia Biogen Idec Moving HQ Back to Cambridge, Constructing Two New Buildings at Kendall Square  Xconomy Trial hit may not be good enough for Sage and Biogen  The Pharma Letter Profits up, Biogen cuts 11% of global workforce  Fortune Biogen Idec. chief executive to retire - The Boston Globe  Boston Globe Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe  Business Wire Biogen Idec Trading Higher on 1.7x Above-Average Volume (BIIB) - Benzinga  Benzinga Which Fund Has The Most To Gain From Biogen Idec?  Benzinga FDA Accepts Biogen's BLA for Alzheimer's Candidate Aducanumab  Genetic Engineering & Biotechnology News Biogen: Big Biotech Play Ready To Move  Seeking Alpha Exclusive: Biogen prices hemophilia drug on par with older therapies  Reuters Biogen Idec Set to Join the S&P 100; Keurig Green Mountain to Join the S&P 500; Changes to the S&P MidCap 400 and the S&P SmallCap 600  PR Newswire UPDATED: Germany gives an initial 'no additional benefit' on Biogen Idec's Tecfidera  FiercePharma Biogen Idec, Atlas Venture Pump $17M into Ataxion  Genetic Engineering News Biogen Idec CEO Jim Mullen Stepping Down, After Tumultuous Year of Shareholder Activism  Xconomy Biogen CEO has 'mixed emotions' as he leaves company after 6 years  CNBC Ataxion Announces $17M Series A Financing from Atlas Venture and Biogen Idec  Business Wire Biogen to pay Forward Pharma $1.25 billion to protect MS drug  Reuters Classen Immunotherapies, Inc. v. Biogen IDEC (Fed. Cir. 2011)  Patent Docs Biogen Must Face FCA Suit Minus 17 State-Level Claims  Law360
For more news about Biogen Idec Inc. click here:
Biogen Idec Inc. News 

Search the Internet:

Website Width:
Bookmark and Share

 Background image:

Copyright@2010-2021 -, all rights reserved.
Investment Forum Stock Quotes Investment News Investment Chat Disclaimer Webmaster Resources